At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating 18F-Fluoromisonidazole, Cediranib Maleate, and 3 other interventions for Advanced Malignant Solid Neoplasm and 25 related conditions. Active but no longer recruiting, targeting 122 participants across 16 sites in 2 countries.
Signals
Detailed Summary
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.
Study Details
Timeline
Arms & Interventions
Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.
Interventions
Correlative studies
Given PO
Correlative studies
Given PO
Correlative studies